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A B S T R A C TObjectives: This research evaluated the psychometric properties of a
new Psoriasis Symptom Diary, identiﬁed diary responder deﬁnitions
for use in determining whether a patient has experienced clinically
meaningful change, and reﬁned diary item content for use in future
clinical trials. Methods: The Psoriasis Symptom Diary was adminis-
tered in a phase 2 clinical trial of AIN457 to US adult outpatients
(N ¼ 172) with physician-diagnosed moderate to severe chronic plaque-
type psoriasis. Participant compliance with daily diary administration
and item score variability, reliability, construct and discriminant
validity, sensitivity to change, and interpretation were all evaluated.
Results: Participants completed 94% of scheduled diary assessments
across 12 study weeks. Diary items were generally normally distributed,
and no ﬂoor or ceiling effects were observed. Item reliability (reprodu-
cibility) was acceptable (intraclass correlation coefﬁcients 4 0.80), with
an exception for one item (skin color). At week 12, items signiﬁcantly
related to criterion measures as predicted (Psoriasis Area and Severitysee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.07.002
rner-Bowker@ert.com.
ndence to: Diane M. Turner-Bowker, 18 Lori EllenIndex r ¼ 0.27–0.57; Investigator’s Global Assessment r ¼ 0.25–0.59),
with the exception of items that measured skin color and difﬁculty
using hands. Most items generated change scores that were synchro-
nous to changes as measured by the Psoriasis Area and Severity Index,
Investigator’s Global Assessment, Dermatology Life Quality Index (r 4
0.37), as well as the Patient Global Impression of Change. Responders
experienced a 2- to 3-point and 3- to 5-point change in item scores for
minimal and large improvements, respectively. Four items that did not
perform well were dropped from the diary. Conclusions: The 16-item
Psoriasis Symptom Diary demonstrated favorable psychometric prop-
erties and is a brief, useful tool for measuring patient-based symptoms
and the impact of chronic plaque psoriasis.
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Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Psoriasis is a chronic inﬂammatory disease of the skin with
prevalence rates estimated between 2.2% and 4.6% in the United
States [1]. Patients with the most common form, plaque psoriasis,
demonstrate red and white scaly patches and plaques (most
frequently on the knees, elbows, palms of hands, soles of feet,
scalp, and genitals). Many patients experience localized plaques,
though for some, psoriasis covers the entire body. Common
symptoms reported by patients with plaque psoriasis include
plaque-related pain, changes in skin appearance, and pruritus [2].
The impact of psoriasis on health-related quality of life is
substantial [3]; in fact, reductions in physical and emotional
functioning are comparable to those reported for major medical
conditions such as cancer, arthritis, hypertension, heart disease,
diabetes, and depression [4]. Psoriasis’ impact on daily activities,
social relationships, work productivity, sleep, body image, and
sexual and other functional areas has been reported in several
studies [5–11]. Because patients’ experience of psoriasis varies
greatly from person to person and because some treatmenteffects are known only to patients, the assessment of disease
severity and outcomes from the patient perspective is especially
important for comprehensive health assessment and clinical
decision making.
Clinician measures of psoriasis have traditionally been used
in trials and practice. And, while existing clinician-reported
instruments capture valuable aspects of disease severity and
outcomes, there are notable limitations [12]. For instance, the
Psoriasis Area and Severity Index (PASI) is used by clinicians to
assess the severity of psoriatic lesions on the basis of area
coverage and plaque appearance. Although it is one of the most
widely used measures in psoriasis research, the PASI has been
criticized as limited by insufﬁcient interrater reliability and
construct validity, and lack of sensitivity and consensus on
interpretability [12–15]. Also, clinician measures such as the PASI
may not reﬂect the most important aspects of psoriasis to the
patient. For instance, the PASI is only modestly correlated with
patient-reported outcome (PRO) measures of psoriasis, and many
patients who are categorized as a “treatment success” on the
PASI report dissatisfaction with their condition [16,17]. PROociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Drive, Smithﬁeld, RI 02917, USA.
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can effectively complement clinician measures as an indicator of
disease status and treatment beneﬁt in studies with patients with
chronic plaque psoriasis [18].
Various PRO measures have been used to assess patients with
psoriasis, including generic PRO measures (e.g., short-form 36
health survey and EuroQol ﬁve-dimensional [EQ-5D] question-
naire), which do not address psoriasis-speciﬁc symptoms and
impacts, and dermatology-speciﬁc instruments including the
Dermatology Life Quality Index (DLQI), Skindex-29, Skindex-16,
Psoriasis Symptom Assessment, Koo-Menter Psoriasis Instru-
ment, the Psoriasis Disability Index, and the QualiPso Question-
naire [17,19–24]. While these measures assess varied aspects of a
patient’s daily life, it is not clear whether any of them adequately
measures the signs and symptoms of psoriasis. Because signs and
symptoms are more directly related to underlying disease pathol-
ogy than other indicators [25], sign/symptom measures may be
more sensitive to treatment effects and may be more likely to
support label claims in a regulatory context than more generic
concepts, such as quality of life [26]. Existing dermatology-speciﬁc
PRO measures may not include symptoms and impacts that are
most relevant to patients with psoriasis. Other potential limita-
tions include numerous items, relatively long recall periods, no
measure of symptom severity, or assessment of multiple symp-
toms in a single item.
The Psoriasis Symptom Diary (referred to here as “Psoriasis
Diary”) was developed to address the limitations of existing
instruments. Psoriasis Diary items were constructed on the basis
of results from qualitative interviews with patients and psoriasis
experts and a review of the published literature [2]. Items address
key symptoms (severity and bother) and functional impacts that
are most relevant to patients with chronic plaque psoriasis,
including psoriasis-related pruritus, stinging, burning, pain, pain
from cracking, scaling, affected skin color, embarrassment due to
plaques, avoidance of activities with other people due to plaques,
and difﬁculties with mobility due to plaques, including bending
joints, walking, and using hands and ﬁngers. Because of potential
variability in signs and symptoms during and across days, partic-
ularly in the context of a clinical trial in which treatment is
administered, the Psoriasis Diary was developed as a daily diary.
Previous work on the Psoriasis Diary established the content
validity of the measure and demonstrated patient understanding
of instructions, items, and response scales [2]. The present study
focuses on the Psoriasis Diary item-level scores and their per-
formance and is not intended to address the potential for scaling
and broader applications of the measure, which may be the
subject of future research. The speciﬁc objectives of the current
research were to 1) examine the quantitative psychometric
characteristics of 20 items comprising the Psoriasis Diary, 2)
identify responder deﬁnitions that can be used to determine
whether a patient has experienced clinically meaningful change
on the diary items, and 3) reﬁne the item content for a version of
the measure that can be used in future clinical trials.Methods
Study Design
This multicenter, parallel-group, randomized, double-blind, pla-
cebo controlled trial assessing the efﬁcacy and safety of a new
treatment for chronic plaque psoriasis consisted of four periods:
screening, induction treatment, maintenance treatment, and
follow-up. The screening period lasted up to 4 weeks and was
used to assess eligibility and to taper patients off disallowed
medications. Eligible patients were randomized to one of the
induction treatment arms, 1) induction with single injection—“Single”: AIN457 150 mg subcutaneously administered at ran-
domization (or baseline); 2) induction with monthly injections
—“Monthly”: AIN457 150 mg subcutaneously administered at
randomization, week 4, and week 8; 3) early loading induction
—“Early”: AIN457 150 mg subcutaneously administered at ran-
domization, week 1, week 2, and week 4; or 4) “Placebo” admin-
istered at randomization, week 1, week 2, week 4, and week 8,
and received study medication according to the treatment sched-
ule of their assigned treatment arm up to week 12.
Sample
Adult (ages Z18 years) outpatients with physician-diagnosed
moderate to severe chronic plaque-type psoriasis for at least 6
months at the time of randomization were eligible to participate
in the study. Patients were required to have a PASI score of 12 or
more, 10% or more body surface area affected by plaque psoriasis,
and Investigator’s Global Assessment (IGA) score of 3 or more to
ensure that the enrolled sample included patients with moderate
to severe psoriasis. Eligible patients’ psoriasis was inadequately
controlled by topical treatment, phototherapy, and/or previous
systemic therapy at the time of screening and randomization.
Participants were excluded from the study if they had forms of
psoriasis other than the chronic plaque-type, drug-induced psor-
iasis, or known immunosuppression (e.g., AIDS) at screening or
randomization; active tuberculosis at screening; or active sys-
temic infections, ongoing use of prohibited psoriasis or other
treatments/medications, use of other biological agents, systemic
psoriasis treatments or photochemotherapy (i.e., psoralen plus
ultraviolet light therapy), phototherapy (i.e., ultraviolet A light,
ultraviolet B light) or topical psoriasis treatments, or any inves-
tigational psoriasis or nonpsoriasis drug use prior to
randomization.
Measures
Psoriasis Symptom Diary
The Psoriasis Symptom Diary (or “Psoriasis Diary”) is a 20-item
electronic daily (24-hour recall) assessment that measures psor-
iasis symptoms and impact on functional health [2]. Symptom
items assess the severity and bother of psoriasis-related itching,
stinging, burning, pain, scaling, and skin color. Impact items
assess the embarrassment, avoidance of activities with other
people, and movement restriction that psoriasis is known to
impose on individuals with the condition. Symptom severity,
bother, and impact items use a 0 to 10 numerical rating scale,
with higher scores indicating more severe symptoms, bother, or
impact. Color of psoriasis-affected skin is assessed by using a
categorical rating scale (pink; light red or brown; bright red or
purple; deep dark red, purple, or brown; gray, white, or silver).
Symptom bother items are administered only if a patient selects
a numerical rating scale rating greater than 0 on the correspond-
ing symptom severity item (i.e., he or she reported experiencing
the psoriasis-related symptom on a given day) (see Table 1).
Criterion measures used to evaluate the Psoriasis Diary
included the following.PASI [27]
The PASI was used in evaluating construct validity at baseline
and week 12, sensitivity to change (baseline to week 12), and the
interpretation of change scores (responder analysis, day 85
administration) produced by the Psoriasis Diary. At week 12, the
PASI score classiﬁed participants as treatment responders
(patients achievingZ75% improvement [reduction] from baseline
PASI score [also referred as PASI 75]), partial responders (patients
achieving a Z50% improvement from baseline PASI score [PASI
Table 1 – Item content, descriptives during baseline week, and test-retest reliability during screening weeks.
Psoriasis Symptom Diary item Response options
(0–10 NRS)*
n Mean Median SD Min Max Reliability
analysis
(ICC; 95% CI)
1. Overall, how severe was your psoriasis-
related itching over the past 24
hours?
0 ¼ No itching 169 6.43 7.00 2.46 0 10 .91 (.88– .94)
10 ¼ Itching as bad as you
can imagine
2. Overall, how bothered were you by your
psoriasis-related itching over the
past 24 hours?
0 ¼ Not bothered at all 168 6.61 7.17 2.46 1 10 .91 (.88– .94)
10 ¼ Bothered as bad as
you can imagine
3. Overall, how severe was your psoriasis-
related stinging over the past 24
hours?
0 ¼ No stinging 169 4.92 5.29 2.90 0 10 .92 (.89– .95)
10 ¼ Stinging as bad as
you can imagine
4. Overall, how bothered were you by your
psoriasis-related stinging over the
past 24 hours?
0 ¼ Not bothered at all 159 5.48 5.50 2.67 0 10 .91 (.88–.94)
10 ¼ Bothered as bad as
you can imagine
5. Overall, how severe was your psoriasis-
related burning over the past 24
hours?
0 ¼ No burning 169 4.67 4.71 3.00 0 10 .94 (.92– .96)
10 ¼ Burning as bad as
you can imagine
6. Overall, how bothered were you by your
psoriasis-related burning over the
past 24 hours?
0 ¼ Not bothered at all 151 5.54 5.43 2.53 0 10 .90 (.85– .93)
10 ¼ Bothered as bad as
you can imagine
7. Overall, how severe was the pain from
your psoriasis-affected skin cracking
over the past 24 hours?
0 ¼ No pain 169 4.88 5.00 2.96 0 10 .93 (.90– .95)
10 ¼ Pain as bad as you
can imagine
8. Overall, how bothered were you by the
pain from your psoriasis-affected
skin cracking over the past 24 hours?
0 ¼ Not bothered at all 159 5.46 5.57 2.71 0 10 .89 (.84–.92)
10 ¼ Bothered as bad as
you can imagine
9. Overall, how severe was your psoriasis-
related pain over the past 24 hours?
0 ¼ No pain 169 4.75 4.75 2.98 0 10 .93 (.90– .95)
10 ¼ Pain as bad as you
can imagine
10. Overall, how bothered were you by
your psoriasis-related pain over the
past 24 hours?
0 ¼ Not bothered at all 155 5.49 5.43 2.64 0 10 .90 (.86– .93)
10 ¼ Bothered as bad as
you can imagine
11. Overall, how severe was your psoriasis
scaling over the past 24 hours?
0 ¼ No scaling 169 6.61 7.00 2.34 0 10 .90 (.87– .93)
10 ¼ Scaling as bad as you
can imagine
12. Overall, how bothered were you by
your psoriasis scaling over the past
24 hours?
0 ¼ Not bothered at all 168 6.72 7.14 2.43 0.4 10 .91 (.88– .94)
10 ¼ Bothered as bad as
you can imagine
13. Overall, what was the color of most of
your psoriasis-affected skin over
the past 24 hours?†
A. Pink 169 3.12 3.00 1.42 1 5 .75 (.67– .82)
B. Light red or brown
C. Bright red or purple
D. Deep dark red, purple,
or brown
E. Gray, white, or silver
14. Overall, how noticeable did you think
the color of your psoriasis-affected
skin was over the past 24 hours?
0 ¼ Not at all noticeable 169 7.28 7.83 2.42 0 10 .93 (.90– .95)
10 ¼ Noticeable as bad as
you can imagine
15. Overall, how much did you try to hide
your psoriasis-affected skin over
the past 24 hours?
0 ¼ Did not try to hide
at all
169 6.65 7.60 3.04 0 10 .92 (.88– .94)
10 ¼ Totally avoided being
seen by others
16. Overall, how much did your psoriasis
cause you to avoid activities with
other people over the past 24
hours?
0 ¼ You did not avoid
other people
169 4.66 5.43 3.58 0 10 .96 (.95–.98)
10 ¼ Avoided other people
as much as you ever
have
17. Overall, how embarrassed were you
because of your psoriasis over the
past 24 hours?
0 ¼ No embarrassment 169 6.50 7.43 3.16 0 10 .94 (.91– .95)
10 ¼ Embarrass-
ment as bad as you can
imagine
18. In the past 24 hours, how hard was it
to bend your joints because of the
psoriasis on your skin?†
0 ¼ Not hard 169 2.64 1.71 2.80 0 10 .92 (.89– .95)
10 ¼ As hard as you can
imagine
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19. In the past 24 hours, how hard was it
to walk because of the psoriasis on
your skin?†
0 ¼ Not hard 169 2.33 1.00 2.82 0 10 .95 (.92– .96)
10 ¼ As hard as you can
imagine
20. In the past 24 hours, how hard was it
to use your hands or ﬁngers because
of the psoriasis on your skin?†
0 ¼ Not hard 169 2.06 1.00 2.64 0 10 .94 (.92–.96)
10 ¼ As hard as you can
imagine
CI, conﬁdence interval; ICC, intraclass correlation coefﬁcient; NRS, numerical rating scales.
 All 0 to 10 scales are NRS, with unlabeled numbers in between the labeled anchors.
† Not included in the ﬁnal 16-item Psoriasis Symptom Diary.
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a PASI score reduction of at least 50% from baseline).IGA (based on Ellis and Krueger [28])
The IGA was used to evaluate discriminant validity of the
Psoriasis Diary at baseline and week 12, and in the analysis of
sensitivity to change (baseline to week 12). The IGA score is
meant to reﬂect overall psoriatic disease state in terms of
coloration, thickness, and scaling of the psoriatic lesions, and
IGA scores range from 0 (clear; no signs of psoriasis [post-
inﬂammatory hyperpigmentation may be present]) to 5 (very
severe disease; deep dark red coloration, very severe thickening
with hard edges, very severe/very coarse scaling covering all
lesions).DLQI [24,29]
The DLQI was used to evaluate construct validity of the Psoriasis
Diary at week 1 and sensitivity to change (week 1 to week 12).EQ-5D questionnaire [30,31]
The EQ-5D questionnaire was used to evaluate construct validity
of the Psoriasis Diary at week 1.Patient’s Assessment of Pruritus Visual Analogue Scale [32]
The Pruritus visual analogue scale (VAS) was used to evaluate
construct validity of the Psoriasis Diary at week 1.Patient Global Impression of Change [33]
The Patient Global Impression of Change (PGIC) was used for
estimating the minimal important difference of Psoriasis Diary
change scores.Procedure
Physicians completed the PASI and the IGA, and patients completed
the Psoriasis Diary, DLQI, EQ-5D questionnaire, Pruritus VAS, and
PGIC as part of a broader study assessing the efﬁcacy and safety of a
new treatment for chronic plaque psoriasis. Physicians reported
PASI results through an interactive voice response system, and IGA
results were transcribed to an electronic case report form. The
Psoriasis Diary and the PGIC were administered on a hand-held
electronic diary, and the DLQI, the EQ-5D questionnaire, and the
Pruritus VAS were administered on paper and then transcribed to
the electronic case report form. The study protocol was approved by
Quorum Review institutional review board, and all patients pro-
vided written informed consent before participating in the study.Analyses
Psychometric performance of the Psoriasis Diary was evaluated
by using standard analytic procedures and measurement review
criteria developed by the Scientiﬁc Advisory Committee of the
Medical Outcomes Trust [34] and further elaborated by the Food
and Drug Administration [26,35].
Data from a subsample of study participants completing the
measures through week 12 were used in the analysis of measure-
ment properties. Data collected during both the screening and
induction periods of the study were used to evaluate item
reliability, validity, responsiveness, and interpretability. Analyses
focused on baseline, week 1, and week 12 data.
Handling of Data
Daily Psoriasis Diary scores were averaged into a weekly (i.e.,
7 day) score for each item (no subscales were derived through
aggregation across items). Four completed days (consecutive or
nonconsecutive) were necessary to derive a weekly score for each
Psoriasis Diary item; otherwise, data were considered missing for
that week. The last observation carried forward principle was
applied to the PASI, IGA, DLQI, EQ-5D questionnaire, and Pruritus
VAS measurements that were missing at week 12 if at least one
postbaseline assessment was available.
Compliance
Compliance rates were calculated to evaluate participants’ ability
and willingness to self-administer the Psoriasis Diary. Compli-
ance rates reﬂect the number of completed assessments relative
to the total number of evening assessments the participants were
expected to complete across a speciﬁed time period (e.g., 12
weeks) of the study.
Item Distributions
The Psoriasis Diary item scores at baseline were assessed
through an examination of descriptive and frequency statistics.
Item ﬂoor or ceiling effects were concluded if more than 50% of
the participants reported no experience or the highest level of
severity of the symptom, respectively. Item-to-item correlations
were used to evaluate possible redundancy (r 4 0.80) between
Psoriasis Diary items.
Reliability
Intraclass correlation coefﬁcients were calculated to assess
whether the Psoriasis Diary yields reproducible scores during a
stable period (when minimal or no change in the condition is
expected). Analyses were conducted on a subsample (n ¼ 128) of
participants indicating no change (“About the same”) on the PGIC
at a 2-week interval (between week 2 and week 1 of the screening
period/before the ﬁrst study medication administration).
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ability of test scores, was not estimated in this study because
scaling has not yet been evaluated for the Psoriasis Diary.
Construct Validity
Construct validity was evaluated through an examination of
correlations between Psoriasis Diary items and criterion meas-
ures. Pearson and Spearman correlation coefﬁcients were com-
puted between each Psoriasis Diary item and the PASI and the
IGA (baseline, week 12), and the DQLI, the EQ-5D questionnaire,
and the Pruritus VAS (week 1) with the following hypotheses: 1)
Psoriasis Diary symptom severity items would be more strongly
associated with the PASI and the IGA than with the EQ-5D
questionnaire, 2) Psoriasis Diary symptom bother items
would be more strongly correlated with the DLQI than with the
EQ-5D questionnaire, and 3) Psoriasis Diary items on itching
(severity and bother) would be strongly correlated with the
Pruritus VAS.
Discriminant Validity
Analysis of variance was used to evaluate whether the Psoriasis
Diary items were able to distinguish between groups expected to
differ clinically. Clinically distinct groups were deﬁned in two
ways: on the basis of the IGA (mild 0–2, moderate 3, and severe
4–5) and PASI (tertiles) score levels at week 12.
Sensitivity to Change
Sensitivity of the Psoriasis Diary items to actual changes in the
clinical condition over time was assessed by examining correla-
tions between change scores for the Psoriasis Diary and criterion
measures. Change scores were calculated for the Psoriasis Diary,
the PASI, and the IGA (week 12 – baseline) and for the DQLI (week
12 – week 1), and Pearson correlation coefﬁcients were generated
to assess the relationship between change scores. Analysis of
variance was used to examine differences in Psoriasis Diary
mean change scores by PGIC level. In addition, mean change in
Psoriasis Diary scores from baseline to each week up to week 12
was evaluated with Cohen effect size statistics [36].
Responder Deﬁnition
Clinically meaningful change reﬂects the point at which a change
in a score can be interpreted as clinically important, and is used
to understand test scores beyond what is provided for by
“statistically signiﬁcant” results. An anchor-based approach was
used to assess clinically meaningful change in Psoriasis Diary
item scores. Psoriasis Diary symptom severity item scores (means
and SDs) were computed for each level of change reported by the
PGIC items. Minimally important differences were deﬁned as
differences between the scores reported for the “About the same”
group and the group reporting “A little better.”
Another way to evaluate a patient’s response to treatment as
measured by the Psoriasis Diary is to attend to within-person
changes in each study group to determine the proportion of
patients who respond adequately to treatment. At week 12, the
PASI score classiﬁed participants as responders (PASI 75, patients
achieving Z75% improvement [reduction] from baseline PASI
score), partial responders (PASI 50, patients achieving a Z50%
improvement from baseline PASI score but o75%), or nonres-
ponders (patients not achieving a PASI reduction of at least 50%
from baseline PASI score). The PASI responder deﬁnitions were
used to classify patients, the mean Psoriasis Diary symptom
severity scores were computed for each PASI classiﬁcation, and
differences were evaluated for each responder group.Results
A subset of participants (N ¼ 172) from the larger US trial was
used in the current study to evaluate the psychometric properties
of the Psoriasis Diary and included patients who completed the
Psoriasis Diary up to week 12. The number of patients providing
data for each week varied because of some missing data. The
sample ranged in age from 18 to 75 years (mean age ¼ 43.78 
12.57), and was predominantly male (69%) and Caucasian (96%).
Compliance
Of the 1,183 assessment opportunities that were available to the
n ¼ 169 patients during the baseline week, only 57 were missed,
resulting in a compliance rate of 95.2%. When examining the
total number of assessments over the entire database (17,524
assessment opportunities), there were 6.1% (1,072) missed eve-
ning reports, resulting in an overall compliance rate of 93.9%
across the 12 weeks of the study.
Item Distributions
Table 1 presents descriptive statistics for each of the Psoriasis
Diary items during the baseline week. Participants reported
experiencing a variety of psoriasis symptoms and impacts, and
each symptom was reported (score 4 0 on the numerical rating
scale on at least 1 day) by 90% to 99% of the patients during the
baseline week. Psoriasis Diary items were generally normally
distributed, with the exception of three items asking about
difﬁculty moving, which were positively skewed, indicating that
few patients endorsed these effects. No ﬂoor or ceiling effects
were observed from this analysis. Strong correlations were found
for some items (i.e., burning, stinging, and pain), though the
items were retained at this point given that they were uniquely
identiﬁed by patients as important and relevant to them and not
fully represented in existing measures. The question of whether
to ultimately retain them in future versions of the questionnaire
can be addressed on further psychometric evaluation. Severity
and bother items on the same symptom (e.g., itching severity and
itching bother) were highly correlated (r ¼ 0.83–0.97).
Reliability
Intraclass correlation coefﬁcients were acceptable (40.80) [37] for
all items except for color of psoriasis-affected skin (see Table 1).
Construct Validity
Table 2 presents correlations for Psoriasis Diary item scores and
scores produced by the PASI and the IGA at baseline and week 12
and the Pruritus VAS, the DLQI, and the EQ-5D questionnaire VAS
at week 1. Correlations at baseline between Psoriasis Diary items
and the clinician-based PASI and IGA assessments were weak
and nonstatistically signiﬁcant; however, with the exception of
the item assessing difﬁculty using hands, correlations were much
stronger and statistically signiﬁcant at week 12. Psoriasis symp-
tom severity and bother items were signiﬁcantly related to the
DLQI and itching VAS (with the exception of color of skin) but
were not strongly correlated with the EQ-5D questionnaire, as
expected (correlations o 0.25). As predicted, the Psoriasis Diary
symptom severity items were more strongly associated with the
PASI and the IGA than with the EQ-5D questionnaire, and the
Psoriasis Diary symptom bother items were more strongly corre-
lated with the DLQI than with the EQ-5D questionnaire. The
Psoriasis Diary items on itching (severity and bother) strongly
correlated with the Pruritus VAS Scale, as well as with the PASI,
IGA, and DLQI.
Table 2 – Construct validity: Spearman correlations between Psoriasis Symptom Diary items and criterion
measures.
Psoriasis
Symptom Diary
item
PASI
(baseline)
PASI
(week 12)
IGA
(baseline)
IGA
(week 12)
DLQI
(week 1)
EQ-5D
VAS
score (week 1)
Pruritus
VAS (week 1)
1: Severe-itching .060 .568* .004 .584* .494* .041 .558*
2: Bother-itching .030 .503* .008 .521* .482* .033 .533*
3: Severe-stinging .042 .523* .013 .494* .588* .188† .427*
4: Bother-stinging .010 .452* .007 .453* .495* .071 .453*
5: Severe-burning .028 .508* .014 .475* .586* .186† .397*
6: Bother-burning .058 .466* .035 .497* .447* .057 .402*
7: Severe-pain-
cracking
.010 .434* .010 .404* .539* .060 .381*
8: Bother-pain-
cracking
.033 .432* .038 .365* .412* .014 .407*
9: Severe-pain .001 .388* .053 .407* .602* .166† .388*
10: Bother-pain .021 .272* .034 .311* .506* .040 .419*
11: Severe-scaling .013 .492* .007 .572* .434* .081 .371*
12: Bother-scaling .030 .427* .014 .512* .448* .064 .370*
13: Color of skin .017 .262* .135 .292* .096 .031 .081
14: Notice-color .074 .477* .124 .575* .518* .002 .233*
15: Hide skin .063 .441* .001 .531* .627* .032 .148
16: Avoid activities .011 .311* .025 .395* .700* .246* .310*
17: Embarrassed .002 .470* .000 .586* .625* .031 .243*
18: Hard-bend joints .022 .306* .003 .280* .511* .245* .269*
19: Hard-walk .019 .301* .053 .247* .465* .322* .232*
20: Hard-use hands .022 .162 .040 .193† .439* .276* .248*
Note. While both Pearson and Spearman correlation coefﬁcients were examined, only Spearman correlation coefﬁcients are reported because
analyses yielded similar results.
DLQI, Dermatology Life Quality Index; EQ-5DVAS, EuroQol ﬁve-dimensional questionnaire visual analogue scale; IGA, Investigator’s Global
Assessment; PASI, Psoriasis Area and Severity Index; VAS, visual analogue scale.
 P o 0.01.
† P o 0.05.
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Psoriasis Diary item scores signiﬁcantly distinguished between
PASI tertile and IGA severity groups, with the exception of the
item to assess difﬁculty using ﬁngers. Figure 1 demonstrates
discrimination results for the itching severity item.
Sensitivity to Change
Changes in Psoriasis Diary item scores from baseline to week 12
were signiﬁcantly and moderately (r 4 0.37) correlated with
changes in the PASI, IGA, and DLQI, except for items assessing
color of skin, ability to move joints, walk, and use hands (see
Table 3). Statistically signiﬁcant differences were found in Psor-
iasis Diary item mean change scores by PGIC level at 12 weeks
(see Fig. 2; e.g., itching severity). Participants reporting an
improvement on the PGIC had signiﬁcantly higher Psoriasis Diary
mean scores (for all items) than did those who reported that their
psoriasis stayed about the same or worsened. Effect size coef-
ﬁcients were moderate to large (40.40) for most items, with the
exception of items concerning color of skin and difﬁculty bending
joints, walking, and use of hand/ﬁngers.
Responder Deﬁnition
Average changes in the Psoriasis Diary items associated with
clinically meaningful changes in the PGIC, IGA, and PGIC are
shown in Table 4. A “Psoriasis Diary responder” (or a patient
whose Psoriasis Diary scores reﬂect clinically meaningful
improvements) would likely show point changes on itemsranging from 2.0 to 3.0 for minimal change and 3.0 to 5.0 for
larger changes. A patient whose Psoriasis Diary scores reﬂect
clinically meaningful improvements (a Psoriasis Diary "res-
ponder") would likely show point changes on items ranging from
2.0 to 3.0 for minimal change and 3.0 to 5.0 for larger changes.
Diary Revisions
Consistently poor performance was observed for items assessing
color of affected skin, difﬁculty bending joints, difﬁculty walking,
and difﬁculty using hands or ﬁngers; thus, these four items were
dropped from the measure (see Table 1).Conclusions
Psoriasis is a common condition that signiﬁcantly impacts
patients’ daily life. This study examined the psychometric char-
acteristics of a new PRO measure of psoriasis symptoms and
functional impacts, developed to address the most relevant
psoriasis patient experiences and the limitations of existing
instruments. Results from this study provide compelling support
for the psychometric characteristics of the items comprising the
Psoriasis Diary.
Unlike other measures, the Psoriasis Diary is completed daily
by the patient. Daily assessments may be particularly useful for
symptom assessment because for many conditions, symptoms
vary from day to day. Daily assessments, however, could affect
patient compliance. In this study, patients completed greater
than 90% of all scheduled assessments over a 16-week interval.
Fig. 1 – Discriminant validity for itching severity item (week 12). IGA, Investigator’s Global Assessment; PASI, Psoriasis Area
and Severity Index.
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exists, rates at or above 85% to 90% can be interpreted as strong
for clinical trials [38]. In this context, compliance with the
Psoriasis Diary is observed to be excellent and supports the daily
diary approach to measuring psoriasis symptoms and functional
impacts.
Several clinician and PRO instruments exist for measuring
psoriasis disease severity. We expected that the Psoriasis Diary
would be associated, but not redundant, with other clinician and
PRO psoriasis measures. Psoriasis Diary items were unrelated to
the PASI and the IGA at baseline. This ﬁnding is consistent with
prior research that found weak correlations among clinician and
PRO measures at baseline among patients with psoriasis [16,17]
and may be attributed to both restricted range in PASI scores atTable 3 – Correlations between changes in scores on Pso
the DLQI
Psoriasis diary item change:
Baseline to week 12
PASI score change: baseline
to week 12 (n ¼ 147)
1: Severe-itching .606*
2: Bother-itching .593*
3: Severe-stinging .413*
4: Bother-stinging .437*
5: Severe-burning .378*
6: Bother-burning .492*
7: Severe-pain-cracking .378*
8: Bother-pain-cracking .406*
9: Severe-pain .368*
10: Bother-pain .486*
11: Severe-scaling .593*
12: Bother-scaling .551*
13: Color of skin .287*
14: Notice-color .540*
15: Hide skin .477*
16: Avoid activities .372*
17: Embarrassed .506*
18: Hard-bend joints .185
†
19: Hard-walk .151
20: Hard-use hands .177
†
DLQI, Dermatology Life Quality Index; IGA, Investigator’s Global Assessm
 Correlation is signiﬁcant at the 0.01 level (two-tailed).
† Correlation is signiﬁcant at the 0.05 level (two-tailed).baseline (due to inclusion/exclusion criteria) and that each
measure (i.e., patient- vs. clinician-reported) may be assessing
uniquely different concepts associated with the condition. For
instance, a number of concepts assessed by the Psoriasis Diary
(e.g., itch, sting, burn, and pain) are not individually measured
(e.g., the DQLI) or not measured at all (e.g., the PASI) in existing
clinician assessments.
Most Psoriasis Diary items were correlated with the PASI and
the IGA at week 12, and results generally supported our hypoth-
eses: Psoriasis Diary symptom severity items were more strongly
correlated with the PASI and the IGA than with the EQ-5D
questionnaire, and symptom bother items were more strongly
correlated with the DLQI than with the EQ-5D questionnaire. The
Psoriasis Diary itching items (severity and bother), however,riasis Symptom Diary and the PASI, the IGA, and
IGA change: baseline to
week 12 (n ¼ 141)
DLQI change: week 1 to
week 12 (n ¼ 138)
.578* .566*
.546* .530*
.432* .594*
.496* .603*
.428* .576*
.510* .615*
.427* .496*
.497* .543*
.407* .535*
.460* .561*
.604* .572*
.523* .571*
.248* .235*
.595* .597*
.506* .526*
.451* .623*
.565* .599*
.165 .334*
.157 .280*
.187† .234*
ent; PASI, Psoriasis Area and Severity Index.
Fig. 2 – Average change in itching severity score is associated with PGIC rating at 12 weeks. PGIC, Patient Global Impression of
Change.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 1 4 – 1 0 2 2 1021correlated as well with the PASI, the IGA, and the DLQI as they did
with the Pruritus VAS. Results suggest that the Psoriasis Diary is
capturing unique information that may be an important comple-
ment to standard clinician-reported end points in understanding
the efﬁcacy of psoriasis treatments.
The Food and Drug Administration Guidance for Industry [26]
recommends a priori responder deﬁnitions for outcome meas-
ures used in clinical trials. Results from this study identiﬁed
Psoriasis Diary responder deﬁnitions for use in determining
whether a patient has experienced clinically meaningful change
(2–3-point and 3–5-point change in item scores for minimal and
large improvements, respectively).
Although the majority of items performed well in psychomet-
ric testing, four items (assessing color of affected skin, difﬁculty
bending joints, difﬁculty walking, and difﬁculty using hands or
ﬁngers) did not perform as well as others. These items were
dropped, resulting in a 16-item Psoriasis Diary. The item assess-
ing color of affected skin showed poor score reproducibility and
construct validity, and was not sensitive. The three items
assessing difﬁculty moving (bending joints, walking, and using
hands or ﬁngers) had skewed item distributions and were not
sensitive, and showed poor construct (using hands) and discrim-
inant validity (using hands or ﬁngers). It should be noted that
these three items were originally included in the Psoriasis Diary
after the completion of concept evaluation (literature review,Table 4 – Meaningful changes of key Psoriasis Symptom
the IGA.
Psoriasis
Symptom Diary item
PASI response* (n ¼ 147)
Partial (Z50% but
o75% improvement)
Complete (Z75%
improvement)
1: Severe-itching 3.2  2.46 5.1  2.67
3: Severe-stinging 2.3  2.07 3.7  2.65
5: Severe-burning 2.2  2.08 3.5  2.7
7: Severe-pain-
cracking
2.5  2.45 3.8  2.72
9: Severe-pain 2.6  2.52 3.4  2.64
11: Severe-scaling 3.5  2.64 5.5  2.63
14: Notice-color 3.1  2.93 5.2  2.84
IGA, Investigator’s Global Assessment; PASI, Psoriasis Area and Severity
 “Partial” responders were patients achieving a 50% or more (but o75%
responders were patients achieving 75% or more improvement (reductexpert clinician interviews, and patient interviews) and item
generation, with a secondary goal in mind: that these items
may be used in future applications to help discriminate between
patients with and without psoriatic arthritis. Thus, their deletion
is not expected to limit the Psoriasis Diary’s content validity.
Although this study had notable strengths, it also had some
limitations. Our sample included adults with moderate to severe
chronic plaque psoriasis and the sample was primarily white
(96%); thus, results may not be generalizable beyond this type of
sample (e.g., the measure may perform differently in a sample
with different skin types and tones). Additional psychometric
research is needed if the Psoriasis Diary is to be used in clinical
trials with other patient populations. In particular, future studies
should investigate the applicability of the color of psoriasis-
affected skin item to subgroups of all skin tones and evaluate
the quantitative uniqueness of potentially overlapping concepts
including burning, stinging, and pain. This measure was tested in
the context of a carefully controlled clinical trial; future research
should evaluate whether compliance with the assessment is
similar in less controlled situations. Also, while results from this
study demonstrate sound psychometric performance of the Psor-
iasis Diary items, consideration and adjustment for multiplicity
should be made if using individual items as unique study end
points. Future research will investigate the potential for scaling of
the Psoriasis Diary items, which may yield an overall score orDiary items by the PASI response, the PGIC, and
Mean  SD
PGIC improvement (n ¼ 138) IGA improvement
(n ¼ 141)
Little Large
2.2  1.91 4.6  2.52 3.9  2.71
2.1  1.34 3.6  2.64 3.1  2.54
2.1  1.30 3.4  2.68 3.0  2.54
2.2  1.88 3.6  2.72 3.3  2.70
2.2  1.83 3.3  2.61 3.0  2.60
2.3  2.19 4.9  2.75 4.2  2.89
1.6  1.98 4.8  2.80 3.8  3.01
Index; PGIC, Patient Global Impression of Change.
) improvement in PASI score from baseline to week 12. “Complete”
ion) in PASI score from baseline to week 12.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 1 4 – 1 0 2 21022subscale scores from the measure, and associated interpretation
guidelines (responder deﬁnitions, clinically meaningful change).
Understanding the patient’s perspective on their psoriasis can
allow for a more informed assessment of treatment efﬁcacy. The
Psoriasis Symptom Diary indexes the patient’s perspective on
psoriasis symptoms (itch, sting, burn, pain, scaling) and impacts
that are related to the underlying pathophysiology of the disease
and are important to patients. Items from this PRO measure may
be useful for efﬁcacy end points alongside other measures of
disease severity in future clinical trials testing new treatments for
chronic plaque psoriasis.Acknowledgments
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